RGRX (Regenerx Biopharmaceuticals) Cyclically Adjusted PB Ratio: (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerx Biopharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenerx Biopharmaceuticals  (OTCPK:RGRX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Regenerx Biopharmaceuticals Cyclically Adjusted PB Ratio Related Terms


Regenerx Biopharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals Cyclically Adjusted PB Ratio Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RGRX vs MYMX, RGMP, NBRVF: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerx Biopharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Regenerx Biopharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Regenerx Biopharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Regenerx Biopharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2023 was:

Adj_Book=Book Value per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-2.609/301.8360*301.8360
=-2.609

Current CPI (Mar. 2023) = 301.8360.

Regenerx Biopharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201306 -1.892 233.504 -2.446
201309 -1.988 234.149 -2.563
201312 -1.984 233.049 -2.570
201403 -2.326 236.293 -2.971
201406 -2.532 238.343 -3.207
201409 -1.191 238.031 -1.510
201412 -1.690 234.812 -2.172
201503 -3.358 236.119 -4.293
201506 -4.967 238.638 -6.282
201509 -6.034 237.945 -7.654
201512 -6.636 236.525 -8.468
201603 -9.793 238.132 -12.413
201606 -6.994 241.018 -8.759
201609 -6.125 241.428 -7.658
201612 -5.681 241.432 -7.102
201703 -5.516 243.801 -6.829
201706 -5.341 244.955 -6.581
201709 -5.641 246.819 -6.898
201712 -3.749 246.524 -4.590
201803 -1.629 249.554 -1.970
201806 -1.886 251.989 -2.259
201809 -1.561 252.439 -1.866
201812 -1.723 251.233 -2.070
201903 -1.500 254.202 -1.781
201906 -1.335 256.143 -1.573
201909 -1.552 256.759 -1.824
201912 -1.779 256.974 -2.090
202003 -1.825 258.115 -2.134
202006 -2.043 257.797 -2.392
202009 -2.236 260.280 -2.593
202012 -2.117 260.474 -2.453
202103 -2.337 264.877 -2.663
202106 -1.083 271.696 -1.203
202109 -1.302 274.310 -1.433
202112 -1.554 278.802 -1.682
202203 -1.788 287.504 -1.877
202206 -1.994 296.311 -2.031
202209 -2.189 296.808 -2.226
202212 -2.401 296.797 -2.442
202303 -2.609 301.836 -2.609

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.